The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.